NCT03620019 2026-03-27
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
38 trialsNCT03839459 2026-01-28
Denosumab for Smoldering Multiple Myeloma
University of Rochester
Phase 2 Completed
NCT04907539 2025-04-16
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
Redx Pharma Ltd
Phase 2 Completed
NCT04907851 2025-03-17
KEYNOTE-E86
Redx Pharma Ltd
Phase 2 Completed
NCT02129699 2024-09-19
SPLENDOUR
ETOP IBCSG Partners Foundation
Phase 3 Terminated
NCT02613416 2024-08-23
Dmab
Stony Brook University
Phase 2 Completed
NCT03301857 2024-05-20
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
Amgen
Phase 4 Completed
NCT02470091 2024-01-22
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Children's Oncology Group
Phase 2 Completed
NCT00556374 2023-07-27
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Amgen
Phase 3 Completed
NCT00321464 2022-11-08
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
Amgen
Phase 3 Completed
NCT00396279 2022-11-08
Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone
Amgen
Phase 2 Completed
NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT00330759 2022-11-07
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
Amgen
Phase 3 Completed
NCT00680992 2022-09-22
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
Amgen
Phase 2 Completed
NCT03382574 2022-06-14
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
National Cancer Institute (NCI)
Phase EARLY_PHASE1 Terminated
NCT01951586 2021-10-25
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Amgen
Phase 2 Completed
NCT02366130 2021-10-07
Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01077154 2021-09-28
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Amgen
Phase 3 Terminated
NCT03027557 2021-05-25
DENOCINA
Aalborg University Hospital
Phase 3 Completed
NCT01545648 2020-01-02
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
University of California, San Francisco
Phase 2 Terminated
NCT01952054 2019-11-22
Denosumab for Breast Cancer With Bone Mets
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02758132 2019-11-08
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
University of Hawaii
Phase 2 Terminated
NCT01419717 2019-09-24
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
Amgen
Phase 3 Completed
NCT03070002 2018-11-20
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
Northwestern University
Phase 2 Terminated
NCT00838201 2018-10-18
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
Amgen
Phase 3 Completed
NCT00089661 2018-10-17
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
Amgen
Phase 3 Completed
NCT00089674 2018-10-17
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
Amgen
Phase 3 Completed
NCT00286091 2018-10-17
Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer
Amgen
Phase 3 Completed
NCT00896454 2018-10-17
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
Phase 2 Completed
NCT00980174 2018-10-17
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
Amgen
Phase 3 Completed
NCT00321620 2018-08-29
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
Amgen
Phase 3 Completed
NCT00925600 2017-05-30
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
Amgen
Phase 3 Completed
NCT00259740 2017-03-15
Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab
Amgen
Phase 2 Completed
NCT01920568 2017-01-16
A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
GlaxoSmithKline
Phase 3 Completed
NCT01824342 2015-03-05
Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer
Amgen
Phase 3 Completed
NCT00950911 2014-02-11
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
Amgen
Phase 3 Completed
NCT00091832 2014-01-28
Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
Amgen
Phase 2 Completed
NCT00104650 2011-01-24
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
Amgen
Phase 2 Completed